BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Jenburkt Pharmaceuticals Ltd. Share Price

NSE
BSE

BSE : 524731

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

High

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 410.47 1516.92
Expenses N/A N/A
PBT 118.35 439.32
Operating profit 0.0 0.0
Net profit 85.37 320.61

Shareholding Pattern

Promoters (% Holding)

46.64%

Mutual funds (% Holding)

0.00%

Non-Institution (% Holding)

53.25%

FI/Banks/Insurance (% Holding)

0.00%

Government (% Holding)

0.00%

FII

0.00%

About Jenburkt Pharmaceuticals Ltd.

Founded 1985
Managing Director Ashish U Bhuta

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,42,725.29 1,845.20 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 1,82,775.12 6,905.00 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,51,764.01 4,494.00 3,102.00 - 3,102.00
Apollo Hospitals Enterprise Ltd. 1,20,200.38 8,361.00 6,696.50 - 6,696.50
Cipla Ltd. 1,13,007.26 1,398.95 1,165.70 - 1,165.70
Dr. Reddy's Laboratories Ltd. 1,09,098.01 1,308.60 1,148.40 - 1,148.40
Zydus Lifesciences Ltd. 1,04,542.68 1,038.95 835.50 - 835.50
Lupin Ltd. 1,04,222.36 2,279.50 1,836.80 - 1,836.80
Mankind Pharma Ltd. 1,02,422.13 2,479.00 1,909.70 - 1,909.70
Max Healthcare Institute Ltd. 99,587.17 1,023.25 903.00 - 903.00
no-content No Records Found

Latest News

Apr
14
2026
EQUITY Posted on Apr 14th 2026

Jenburkt Pharmaceuticals informs about annual disclosure

Pursuant to SEBI Circular SEBI/HO/DDHS/CIR/2021/613 dated 10th August, 2021 (updated on 13th April, 2022 by SEBI), Jenburkt Pharmaceuticals has confirmed that for the financial year ended on 31st March, 2026, the company is ‘not a large corporate’ as per the applicability criteria mentioned in Clause 2.1 of Chapter XII therein.
The above information is a part of company’s filings submitted to BSE. 
Read More
May
23
2026
EQUITY Posted on May 23rd 2026

Concord Biotech informs about board meeting

Concord Biotech has informed that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026, inter alia, to consider and approve the audited Standalone and Consolidated Financial Results for the fourth quarter and financial year ended March 31, 2026 along with audit report thereon and subject to approval of shareholders at the ensuing Annual General Meeting, to recommend final dividend on equity shares of the Company.

The above information is a part of company’s filings submitted to BSE. 

Read More
May
23
2026
COMPANY Posted on May 23rd 2026

Shilpa Medicare - Quaterly Results

The turnover is pegged at Rs. 2011.10 millions for the March 2026 quarter. The mentioned figure indicates a rise of about 59.35% as against Rs. 1262.10 millions during the year-ago period.The Total Profit for the quarter ended March 2026 of Rs. 709.60 millions grew from Rs.-56.30 millionsOperating Profit saw a handsome growth to 666.80 millions from 486.60 millions in the quarter ended March 2026.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 2011.10 1262.10 59.35 5970.30 4774.10 25.06 5970.30 4774.10 25.06
Other Income 68.90 106.40 -35.24 381.40 696.70 -45.26 381.40 696.70 -45.26
PBIDT 666.80 486.60 37.03 1938.60 2058.00 -5.80 1938.60 2058.00 -5.80
Interest 26.20 19.10 37.17 100.40 58.70 71.04 100.40 58.70 71.04
PBDT 924.30 24.30 3703.70 2032.40 1541.90 31.81 2032.40 1541.90 31.81
Depreciation 144.10 123.40 16.77 551.10 488.60 12.79 551.10 488.60 12.79
PBT 780.20 -99.10 -887.29 1481.30 1053.30 40.63 1481.30 1053.30 40.63
TAX 70.60 -42.80 -264.95 151.60 374.40 -59.51 151.60 374.40 -59.51
Deferred Tax 13.80 -59.40 -123.23 76.60 -96.40 -179.46 76.60 -96.40 -179.46
PAT 709.60 -56.30 -1360.39 1329.70 678.90 95.86 1329.70 678.90 95.86
Equity 195.60 97.80 100.00 195.60 97.80 100.00 195.60 97.80 100.00
PBIDTM(%) 33.16 38.55 -14.00 32.47 43.11 -24.68 32.47 43.11 -24.68
Read More
May
23
2026
COMPANY Posted on May 23rd 2026

Sun Pharma Inds. - Quaterly Results

The sales is pegged at Rs. 49238.80 millions for the March 2026 quarter. The mentioned figure indicates a decline of about -31.42% as against Rs. 71794.50 millions during the year-ago period.The Net Profit of the company slipped to Rs. 6087.00 millions from Rs. 20419.70 millions, a decline of -70.19% on QoQ basis.Operating Profit reported a sharp decline to 13919.00 millions from 31915.80 millions in the corresponding previous quarter.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 49238.80 71794.50 -31.42 207546.40 229774.00 -9.67 207546.40 229774.00 -9.67
Other Income 629.30 1321.30 -52.37 4193.30 3791.40 10.60 4193.30 3791.40 10.60
PBIDT 13919.00 31915.80 -56.39 66000.20 72168.40 -8.55 66000.20 72168.40 -8.55
Interest 2169.20 2323.80 -6.65 9478.40 9538.90 -0.63 9478.40 9538.90 -0.63
PBDT 11749.80 29592.00 -60.29 51058.40 62629.50 -18.48 51058.40 62629.50 -18.48
Depreciation 3259.70 3054.40 6.72 13117.20 12867.40 1.94 13117.20 12867.40 1.94
PBT 8490.10 26537.60 -68.01 37941.20 49762.10 -23.75 37941.20 49762.10 -23.75
TAX 2403.10 6117.90 -60.72 11707.00 7481.30 56.48 11707.00 7481.30 56.48
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 6087.00 20419.70 -70.19 26234.20 42280.80 -37.95 26234.20 42280.80 -37.95
Equity 2399.30 2399.30 0.00 2399.30 2399.30 0.00 2399.30 2399.30 0.00
PBIDTM(%) 28.27 44.45 -36.41 31.80 31.41 1.25 31.80 31.41 1.25
Read More
May
23
2026
COMPANY Posted on May 23rd 2026

Jubilant Pharmova - Quaterly Results

The March 2026 quarter revenue stood at Rs. 703.00 millions, up 15.82% as compared to Rs. 607.00 millions during the corresponding quarter last year.The company almost doubled its revenue to Rs. 572.00 millions  from Rs. 9.00 millions in the quarter ended March 2026.Operating profit surged to 150.00 millions from the corresponding previous quarter of 112.00 millions.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 703.00 607.00 15.82 2635.00 2314.00 13.87 2635.00 2314.00 13.87
Other Income 5.00 3.00 66.67 24.00 202.00 -88.12 24.00 202.00 -88.12
PBIDT 150.00 112.00 33.93 512.00 609.00 -15.93 512.00 609.00 -15.93
Interest 9.00 31.00 -70.97 73.00 129.00 -43.41 73.00 129.00 -43.41
PBDT 54.00 81.00 -33.33 352.00 480.00 -26.67 352.00 480.00 -26.67
Depreciation 13.00 15.00 -13.33 60.00 66.00 -9.09 60.00 66.00 -9.09
PBT 41.00 66.00 -37.88 292.00 414.00 -29.47 292.00 414.00 -29.47
TAX -531.00 57.00 -1031.58 93.00 192.00 -51.56 93.00 192.00 -51.56
Deferred Tax -533.00 7.00 -7714.29 47.00 -13.00 -461.54 47.00 -13.00 -461.54
PAT 572.00 9.00 6255.56 199.00 222.00 -10.36 199.00 222.00 -10.36
Equity 159.00 159.00 0.00 159.00 159.00 0.00 159.00 159.00 0.00
PBIDTM(%) 21.34 18.45 15.64 19.43 26.32 -26.17 19.43 26.32 -26.17
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Jenburkt Pharmaceuticals Ltd. ?

The current share price of Jenburkt Pharmaceuticals Ltd. is ₹1,154.70 as of 2026-05-22.

The market capitalisation of Jenburkt Pharmaceuticals Ltd. is ₹509.60 as of 2026-05-22.

The 1-year return of Jenburkt Pharmaceuticals Ltd. is 0.85% as of 2026-05-22.

The P/E ratio of Jenburkt Pharmaceuticals Ltd. is 13.93 as of 2026-05-23.

The 52-week high and low of Jenburkt Pharmaceuticals Ltd. are ₹1,410.00 and ₹944.00, respectively, as of 2026-05-22.

The dividend yield of Jenburkt Pharmaceuticals Ltd. is 0.0% as of2026-05-22.

You can buy Jenburkt Pharmaceuticals Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Jenburkt Pharmaceuticals Ltd. is Ashish U Bhuta.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore